Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Endocrine 1

Conditions

Neuroendocrine Tumors 7Sarcoma 3Small Cell Lung Carcinoma 2Neoplasms 2Biliary Tract Neoplasms 2Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Lymphoma 1Colorectal Neoplasms 1Carcinoid Tumor 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

Octreotide 5Everolimus 5pasireotide 3lanreotide 2Bevacizumab 2surufatinib 1pembrolizumab 1ganitumab 1fosbretabulin 1epothilone B 1conatumumab 1cixutumumab 1azaspirane 1arginyllysine 1TKM-080301 1Sunitinib 1Rose Bengal 1Random Allocation 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1CX 3543 1Biological Therapy 1Biological Factors 12-Methoxyestradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoid Tumor × surufatinib × Clear all
NCT02549937 2024-07-10

A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors

Hutchmed

Phase 1/2 Completed
130 enrolled 30 charts
EndocrineSarcoma

Carcinoid Tumor, Neoplasms, Sarcoma, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡